- Home
- CRMD vs DNA Comparison
CRMD vs DNA Comparison
Compare CRMD & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRMD | DNA |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 590.7M | 520.6M |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRMD | DNA |
|---|---|---|
| Price | $8.09 | $6.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $14.83 | $8.50 |
| AVG Volume (30 Days) | ★ 1.3M | 978.2K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 780.00 | 46.49 |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $311,709,000.00 | $170,155,000.00 |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.65 | ★ N/A |
| Revenue Growth | ★ 617.03 | N/A |
| 52 Week Low | $6.13 | $5.37 |
| 52 Week High | $14.96 | $17.58 |
Technical Indicators
Market Signals| Indicator | CRMD | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 33.04 |
| Support Level | $8.09 | $6.21 |
| Resistance Level | $8.92 | $7.38 |
| Average True Range (ATR) | 0.39 | 0.55 |
| MACD | 0.08 | -0.15 |
| Stochastic Oscillator | 54.79 | 0.63 |
Price Performance
Historical ComparisonAbout CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.